Search

Displaying results 6151 - 6160 of 6198 in total
  1. Drug

    Plitidepsin

    go.drugbank.com/drugs/DB04977
    Investigational

    Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...

  2. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...

  3. Drug

    Encenicline

    go.drugbank.com/drugs/DB11726
    Investigational

    Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.

  4. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. Camostat mesylate inhibits cholecystokinin, pro-infl...

  5. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  6. Drug

    Dihydroquinidine barbiturate

    go.drugbank.com/drugs/DB01341
    Experimental

  7. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...

  8. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  9. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected...

  10. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).